None listed
Conditions
Interventions
Intervention1: Tofacitinib: we will study and compare clinical efficacy and safety of oral cyclosporine A versus oral Tofacitinib in recalcitrant/refractory vernal and atopic keratoconjunctivitis. Tof
Sponsors
Advance eye center post graduate institute of medical education and research institute
Eligibility
Inclusion criteria
Inclusion criteria: 1)Age: 8-35 years 2)Moderate-severe VKC/AKC (5-5-5 exacerbation scale) 3)Recalcitrant VKC/AKC (relapse within 1 months of topical/oral steroid) Refractory VKC/AKC (Steroid unresponsive /Steroid toxicity)
Exclusion criteria
Exclusion criteria: 1)Patients with ocular diseases other than AKC/VKC 2)Prior systemic immunosuppressant 3)Patients with systemic diseases other than allergic diseases 4)Hepatic/renal dysfunction 5)Pregnant/lactating women 6)Patients not willing to give consent for participation or follow-up 7)Patients with any form of coagulopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Change in total sign score from baseline at 12 weeks 2)Change in total symptom score from baseline at 12 weeksTimepoint: Patients will follow up at 2weeks, 1month and 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Change in individual sign score from baseline at 12 weeks 2)Change in quality-of-life score 3)Change in 5-5-5 exacerbation score of VKC/AKC 4)Number of acute episodes after initiation of treatment 5)Change in visual acuity from baseline at 12 weeks 6)Any associated systemic or ocular side effectsTimepoint: Patients will follow up at 2weeks, 1month and 3 months. | — |
Countries
India
Contacts
Public ContactDr Amit Gupta
Post graduate institute of medical education and research
Outcome results
None listed